Agenus 향후 성장
Future 기준 점검 0/6
Agenus 의 수익은 연간 59.7% 감소할 것으로 예상되는 반면, 연간 수익은 2.4% 로 증가할 것으로 예상됩니다. EPS는 연간 70.2% 만큼 쇠퇴할 것으로 예상됩니다.
핵심 정보
-59.7%
이익 성장률
-70.20%
EPS 성장률
| Biotechs 이익 성장 | 27.7% |
| 매출 성장률 | 2.4% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 11 Aug 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Aug 15
AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside
Agenus sees its analyst fair value estimate move from $30.00 to $19.50 as analysts recalibrate long term assumptions on revenue growth, profitability and future P/E, following recent price target changes related to financing plans and the refocused pipeline. Analyst Commentary Recent Street research on Agenus highlights a mix of optimism about the refocused pipeline and caution around financing and execution.
내러티브 업데이트 • Jul 31
AGEN: Refocused Colon Cancer Program And New Funding Will Drive Upside
Agenus is in focus after analysts lifted their price target to $14 from $8, citing a revised view on fair value, updated growth and margin assumptions, and a higher future P/E multiple following recent research that highlights the company’s refocused oncology pipeline and $340M private placement. Analyst Commentary on Agenus Recent research on Agenus highlights a mix of optimism around the oncology pipeline and the US$340M private placement, alongside some clear areas where analysts see meaningful execution and valuation risks.내러티브 업데이트 • Jul 13
AGEN: Neoadjuvant Colorectal Cancer Focus And Funding Will Drive Bullish Reassessment
Agenus' analyst price target has been reset from $15.50 to $30.00. Analysts point to the company's refocus on botensilimab and balstilimab in neoadjuvant microsatellite stable colorectal cancer, as well as the recently announced $340.0m private placement, as key drivers of their updated view.내러티브 업데이트 • Jun 23
AGEN: Late-Stage Cancer Pipeline And Access Programs Will Drive Future Upside
Analysts have revised their price target on Agenus to reflect a lower assumed future P/E of 24.80x, down from 34.01x, alongside updated views on revenue growth and profit margins that together temper growth expectations while assuming a stronger profitability profile. What’s in the News for Agenus Agenus is advancing its botensilimab plus balstilimab program with new retrospective data using Noetik’s AI based TARIO-2 model to analyze routine H&E tumor images and identify spatial tumor microenvironment patterns linked with clinical outcomes in solid tumors, including microsatellite stable metastatic colorectal cancer, ovarian cancer, and sarcomas, with results to be presented at the 2026 ASCO Annual Meeting.내러티브 업데이트 • Jun 08
AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment
Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.내러티브 업데이트 • May 24
AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).내러티브 업데이트 • May 04
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).내러티브 업데이트 • Apr 20
AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).내러티브 업데이트 • Apr 04
AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.내러티브 업데이트 • Aug 17
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
새로운 내러티브 • Apr 08
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Seeking Alpha • Jul 24
Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking Alpha분석 기사 • May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...분석 기사 • May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 128 | -50 | -44 | N/A | 2 |
| 12/31/2027 | 137 | -26 | -20 | N/A | 2 |
| 12/31/2026 | 140 | 35 | 7 | N/A | 1 |
| 6/30/2026 | 133 | 92 | -99 | -99 | N/A |
| 3/31/2026 | 124 | 64 | -88 | -88 | N/A |
| 12/31/2025 | 114 | 0 | -77 | -77 | N/A |
| 9/30/2025 | 107 | -35 | -89 | -89 | N/A |
| 6/30/2025 | 102 | -166 | -128 | -128 | N/A |
| 3/31/2025 | 100 | -191 | -146 | -146 | N/A |
| 12/31/2024 | 103 | -227 | -159 | -158 | N/A |
| 9/30/2024 | 160 | -228 | -171 | -170 | N/A |
| 6/30/2024 | 160 | -224 | -186 | -182 | N/A |
| 3/31/2024 | 161 | -240 | -212 | -204 | N/A |
| 12/31/2023 | 156 | -246 | -234 | -224 | N/A |
| 9/30/2023 | 101 | -271 | -255 | -231 | N/A |
| 6/30/2023 | 99 | -263 | -234 | -198 | N/A |
| 3/31/2023 | 95 | -240 | -232 | -182 | N/A |
| 12/31/2022 | 98 | -220 | -228 | -175 | N/A |
| 9/30/2022 | 90 | -215 | -199 | -151 | N/A |
| 6/30/2022 | 320 | 18 | -42 | 13 | N/A |
| 3/31/2022 | 310 | -19 | -38 | 0 | N/A |
| 12/31/2021 | 296 | -24 | -24 | 10 | N/A |
| 9/30/2021 | 307 | 4 | -28 | -3 | N/A |
| 6/30/2021 | 69 | -226 | -170 | -166 | N/A |
| 3/31/2021 | 85 | -190 | -150 | -147 | N/A |
| 12/31/2020 | 88 | -181 | -143 | -139 | N/A |
| 9/30/2020 | 91 | -174 | -139 | -135 | N/A |
| 6/30/2020 | 97 | -168 | -135 | -131 | N/A |
| 3/31/2020 | 85 | -171 | N/A | -130 | N/A |
| 12/31/2019 | 150 | -108 | N/A | -19 | N/A |
| 9/30/2019 | 122 | -126 | N/A | -23 | N/A |
| 6/30/2019 | 115 | -113 | N/A | -19 | N/A |
| 3/31/2019 | 115 | -87 | N/A | -14 | N/A |
| 12/31/2018 | 37 | -160 | N/A | -131 | N/A |
| 9/30/2018 | 39 | -147 | N/A | -121 | N/A |
| 6/30/2018 | 29 | -151 | N/A | -123 | N/A |
| 3/31/2018 | 18 | -158 | N/A | -120 | N/A |
| 12/31/2017 | 43 | -121 | N/A | -94 | N/A |
| 9/30/2017 | 40 | -112 | N/A | -84 | N/A |
| 6/30/2017 | 41 | -116 | N/A | -82 | N/A |
| 3/31/2017 | 44 | -113 | N/A | -73 | N/A |
| 12/31/2016 | 23 | -127 | N/A | -80 | N/A |
| 9/30/2016 | 25 | -117 | N/A | -83 | N/A |
| 6/30/2016 | 27 | -89 | N/A | -78 | N/A |
| 3/31/2016 | 27 | -101 | N/A | -72 | N/A |
| 12/31/2015 | 25 | -88 | N/A | -47 | N/A |
| 9/30/2015 | 19 | -98 | N/A | -38 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: AGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.7%).
수익 vs 시장: AGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.7%).
고성장 수익: AGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다.
수익 대 시장: AGEN 의 수익(연간 2.4%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: AGEN 의 수익(연간 2.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: AGEN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/20 20:20 |
| 종가 | 2026/08/20 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Agenus Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |